WaveMan
WaveMan · Company
RLAY · Relay Therapeutics, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

RLAY Relay Therapeutics (RLAY) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001812364
Quote by TradingView
Form 144 · 6
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
164
13F, latest reported quarter
Conversions, 180 days
4
Codes C/M, not in net · $1.2M priced

What the filings say about RLAY

Insiders, 180 days
-$11.5M net sold
4 sellers · 32% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$129.5M
6 notices

Relay Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Relay Therapeutics, Inc. insiders sold a net $11.5M of stock across 249 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
Patel Sanjiv
President and CEO
SELL
2026-10-08 SECtraded 2026-10-07
48,199
$872.4K
+1.7%
Context
  • 36 earlier Form 4 trades (code P or S) here by this insider (36 sales), the last on Sep 8, 2026.
  • The trade is 10.2% of the 471,301 shares held after it.
  • 2 other insiders sold within 30 days.
  • 164 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Patel Sanjiv sold about $872.4K of RLAY under a 10b5-1 plan on Oct 7, 2026; 2 other insiders sold within 30 days and 164 funds added in the latest 13F quarter.
Catinazzo Thomas
Chief Financial Officer
SELL
2026-10-08 SECtraded 2026-10-06
17,511
$325.4K
+1.7%
Context
  • 64 earlier Form 4 trades (code P or S) here by this insider (64 sales), the last on Sep 8, 2026.
  • The trade is 16.6% of the 105,340 shares held after it.
  • 2 other insiders sold within 30 days.
  • 164 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Catinazzo Thomas sold about $325.4K of RLAY under a 10b5-1 plan on Oct 6, 2026; 2 other insiders sold within 30 days and 164 funds added in the latest 13F quarter.
Catinazzo Thomas
Chief Financial Officer
SELL
2026-10-08 SECtraded 2026-10-06
206
$4.0K
+1.7%
Context
  • 64 earlier Form 4 trades (code P or S) here by this insider (64 sales), the last on Sep 8, 2026.
  • The trade is 0.2% of the 105,134 shares held after it.
  • 2 other insiders sold within 30 days.
  • 164 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Catinazzo Thomas sold about $4.0K of RLAY under a 10b5-1 plan on Oct 6, 2026; 2 other insiders sold within 30 days and 164 funds added in the latest 13F quarter.
Patel Sanjiv
President and CEO
SELL
2026-09-09 SECtraded 2026-09-08
48,199
$912.9K
-3.8%
Context
  • 35 earlier Form 4 trades (code P or S) here by this insider (35 sales), the last on Aug 17, 2026.
  • The trade is 9.3% of the 519,500 shares held after it.
  • 3 other insiders sold within 30 days.
  • 164 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Patel Sanjiv sold about $912.9K of RLAY under a 10b5-1 plan on Sep 8, 2026; 3 other insiders sold within 30 days and 164 funds added in the latest 13F quarter.
Bergstrom Donald A
President, R&D
SELL
2026-09-09 SECtraded 2026-09-08
8,530
$161.8K
-3.8%
Context
  • 59 earlier Form 4 trades (code P or S) here by this insider (59 sales), the last on Jul 28, 2026.
  • The trade is 2.1% of the 399,130 shares held after it.
  • 3 other insiders sold within 30 days.
  • 164 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President, R&D Bergstrom Donald A sold about $161.8K of RLAY under a 10b5-1 plan on Sep 8, 2026; 3 other insiders sold within 30 days and 164 funds added in the latest 13F quarter.
249 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 244 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$11.5M over 180 days
-$4.0M over 90 days
below 85% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
164 funds bought in last quarter
more than 85% of Pharma & Biotech
Revenue
+53.4% year over year
more than 77% of Pharma & Biotech
Margin
-1800.6% net margin
below 90% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
32.1% of the float short (float per yahoo 2026-10-26) · 12.6 days to cover · settled 2026-09-30
more than 95% of Pharma & Biotech
What changed in the last 30 days
Oct 8President and CEO Patel Sanjiv sold $872.4K under a 10b5-1 plan (Oct 7)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 8Chief Financial Officer Catinazzo Thomas sold $329.3K under a 10b5-1 plan (Oct 6)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 7Director SANJIV PATEL filed to sell $1.8M by Oct 7 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Oct 6Officer THOMAS CATINAZZO filed to sell $1.8M by Oct 6 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.

Watch RLAY

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+180.6%12M
-7%+69%+145%+220%2025-102025-122026-022026-042026-062026-082026-10 2026-06-22 · Bergstrom Donald A sold $1.6M2026-06-22 · Catinazzo Thomas sold $1.0M2026-08-17 · Patel Sanjiv sold $979.9K2026-06-22 · Catinazzo Thomas sold $955.8K2026-06-30 · Rahmer Peter sold $954.5K2026-07-07 · Patel Sanjiv sold $943.7K2026-09-08 · Patel Sanjiv sold $912.9K2026-06-22 · Catinazzo Thomas sold $875.0K2026-10-07 · Patel Sanjiv sold $872.4K2025-11-03 · Patel Sanjiv sold $434.5K2026-08-14 · Catinazzo Thomas sold $349.7K2026-01-06 · Patel Sanjiv sold $337.6K2026-09-08 · Catinazzo Thomas sold $335.6K2026-07-06 · Catinazzo Thomas sold $331.1K2026-10-06 · Catinazzo Thomas sold $325.4K2026-06-22 · Catinazzo Thomas sold $301.4K2026-04-07 · Catinazzo Thomas sold $230.5K2026-05-14 · Catinazzo Thomas sold $227.8K2025-10-28 · Bergstrom Donald A sold $225.2K2026-03-09 · Catinazzo Thomas sold $178.2K2026-07-06 · Bergstrom Donald A sold $162.0K2026-09-08 · Bergstrom Donald A sold $161.8K2025-10-29 · Rahmer Peter sold $160.5K2025-10-28 · Catinazzo Thomas sold $157.9K2026-01-27 · Bergstrom Donald A sold $144.0K2025-10-28 · Rahmer Peter sold $139.5K2026-01-27 · Catinazzo Thomas sold $105.3K2026-08-26 · Rahmer Peter sold $90.3K2026-01-27 · Rahmer Peter sold $89.0K2026-07-28 · Bergstrom Donald A sold $41.6K2026-07-28 · Catinazzo Thomas sold $27.2K2026-04-09 · Catinazzo Thomas sold $27.0K2026-01-28 · Bergstrom Donald A sold $22.7K2026-04-28 · Bergstrom Donald A sold $22.0K2026-04-28 · Catinazzo Thomas sold $14.4K2026-01-28 · Catinazzo Thomas sold $14.3K2026-07-28 · Rahmer Peter sold $13.9K2026-01-28 · Rahmer Peter sold $11.4K2026-04-28 · Rahmer Peter sold $11.1K2026-10-06 · Catinazzo Thomas sold $4.0K2026-10-07 · SANJIV PATEL filed to sell $1.8M2026-10-06 · THOMAS CATINAZZO filed to sell $1.8M2026-08-26 · PETER RAHMER filed to sell $1.0M2026-08-25 · SVF Pauling (Cayman) Ltd filed to sell $123.4M2026-08-04 · SEKAR KATHIRESAN filed to sell $826.5K2026-07-31 · SEKAR KATHIRESAN filed to sell $563.6K2026-07-21 · SEKAR KATHIRESAN filed to sell $594.4K2026-07-20 · SEKAR KATHIRESAN filed to sell $1.3M2026-07-07 · SANJIV PATEL filed to sell $2.7M2026-06-30 · PETER RAHMER filed to sell $987.0K2026-06-22 · DONALD BERGSTROM filed to sell $1.8M2026-06-22 · THOMAS CATINAZZO filed to sell $3.3M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns RLAY: institutional holders (13F)

13F holdings, latest reported quarter
SB INVESTMENT ADVISERS (UK) LTD
27,904,963 sh
$522.1M
FMR LLC
20,110,113 sh
$376.3M
Casdin Capital, LLC
16,035,240 sh
$300.0M
BlackRock, Inc.
15,288,202 sh
$286.0M
PERCEPTIVE ADVISORS LLC
14,106,187 sh
$263.9M

Congress trades in RLAY

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

RLAY planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
SANJIV PATEL
Filed 2026-10-07
$1.8M
THOMAS CATINAZZO
Filed 2026-10-06
$1.8M
PETER RAHMER
Filed 2026-08-26
$1.0M
SVF Pauling (Cayman) Ltd
Filed 2026-08-25
$123.4M
SEKAR KATHIRESAN
Filed 2026-08-04
$826.5K

RLAY mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Invesco Dorsey Wright Healthcare Momentum ETF
$5.3M position · as of 2026-07-31
2.2%
ALPS Medical Breakthroughs ETF
$2.6M position · as of 2026-05-31
1.6%
Fidelity Advisor Biotechnology Fund
$34.8M position · as of 2026-07-31
1.6%
Tema Oncology ETF
$2.3M position · as of 2026-05-31
1.3%
Harbor Small Cap Growth Fund
$31.7M position · as of 2026-07-31
1.2%
State Street(R) SPDR(R) S&P(R) Biotech ETF
$118.0M position · as of 2026-06-30
1.1%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
5 registered trials, 4 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
3
Phase 1
2 active
1
Phase 2
1 active
1
Phase 3
1 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$4.6M
$9.1M
$1.6M
-80%
+20%
2024
$13.1M
-$1.3M
$5.1M
-90%
-9%
2023
$19.8M
$5.3M
$6.3M
-74%
-8%
2022
$8.1M
-$5.2M
$2.8M
-64%
-11%
2021
$8.5M
-$3.4M
$2.3M
-26%
-1%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $11.5M sold by insiders over 180 days, 164 funds added last quarter, $129.5M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

RLAY financials

Revenue growth
+53.4%
XBRL, annual
Net margin
-1800.6%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$10.3M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-2,764%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$212.6M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-36.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-33.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-38.5%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
-5.3%
TTM free cash flow over market value at close 2026-10-23
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$15.4M$10.0M$25.5M$1.4M
Operating income-$302.7M-$372.5M-$373.0M-$299.3M
Net income-$276.5M-$337.7M-$342.0M-$290.5M
EPS (diluted)-1.61-2.36-2.79-2.59
Operating cash flow-$235.5M-$249.1M-$300.3M-$229.5M
Cash$84.0M$124.3M$143.7M$151.8M
SEC XBRL, fiscal years, as known on 2026-10-27

RLAY Stock Sonar score 5/7 axes

Find similar shapesCompare

RLAY ranks highest on institutional and government (85th percentile) and growth (77th), and lowest on insider conviction (8th), among Pharma & Biotech peers.

ProfitGrowthInsidersInstitutionsRisk
Profitability
60
Inputs
  • Return on equity-36.8% · 63 pct, sector of 545
  • Return on assets-33.7% · 57 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-38.5% · 60 pct, sector of 576
Growth
77
Inputs
  • Revenue growth, YoY+53.4% · 77 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
8
Inputs
  • Net Form 4 buying (codes P and S), 180d-$8.8M · 15 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
85
Inputs
  • Funds adding, latest quarter164 · 85 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
39
Inputs
  • Short interest, % of float+32.1% · 3 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+6.6% · 75 pct, sector of 511
2 not measured: Financial health, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

RLAY filings, in plain words

Are Relay Therapeutics insiders buying or selling RLAY?

In the 180 days to 2026-10-27, Relay Therapeutics insiders were net sellers, a net $11.5M across purchases and sales reported on Form 4, by 4 sellers.

Are there planned insider sales of RLAY?

Yes. 6 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $129.5M of stock; the latest, by SANJIV PATEL, was filed 2026-10-07.

Read the full summary

In the 180 days to 2026-10-27, Relay Therapeutics insiders were net sellers of RLAY, a net $11.5M across purchases and sales reported on Form 4 by 4 sellers. 32% of the 22 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 6 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $129.5M of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies